TheEdgeResearch
Home / Stocks / CRBU

Caribou Biosciences, Inc. (CRBU)

NASDAQ Healthcare Biotechnology
$0.28 ▼ -8.44%
Market Cap
$30.7M
Sector
Healthcare
Industry
Biotechnology
Beta
2.49
52-Wk Range
0.2819-2.49
CEO
Rachel E. Haurwitz
Country
US
Currency
USD

Caribou Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Berkeley, CA, US. The stock last traded at $0.28, down 8.44% on the session, giving a market capitalisation of $30.7M. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of -1085.0%. Its beta of 2.49 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.28
Price / Sales
3.25
Price / Book
0.40
EV / EBITDA
-0.30
Gross margin
93.1%
Operating margin
-1140.6%
Net margin
-1085.0%
Return on equity
—
Debt / equity
0.34
Current ratio
4.97
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
97
IPO date
2021-07-23
Headquarters
Berkeley, CA, US
About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

Comparable companies

Caribou Biosciences, Inc. is most often compared with the following Healthcare names:

AARDALLOENTAFHTXHUMAIVAOBIOPRLDPYXSTNYA
More research on CRBU
CRBU technical analysis CRBU TheEdge Score Compare against peers
Open full interactive analysis & DCF →